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Abstract
Introduction: Single nucleotide polymorphisms (SNPs) of transforming growth factor b (TGF-b) and IL-6 genes
(respectively, 869C/T and -174G/C) have been associated with radiographic severity of bone-erosive damage in
patients with rheumatoid arthritis (RA). Musculoskeletal ultrasound (US) is more sensitive than radiography in
detecting bone erosion. We analyzed the association between TGF-b 869C/T and IL-6 -174G/C SNPs and bone-
erosive damage, evaluated by US, in a cohort of patients with severely active RA.
Methods: Seventy-seven patients were enrolled before beginning anti-TNF treatment. Disease activity was
measured using the disease activity score in 28 joints, and the clinical response was evaluated according to the
European League Against Rheumatism response criteria. Rheumatoid factor (RF) and anticitrullinated protein/
peptide antibodies (ACPAs) were detected. The 869C/T TGF-b and -174G/C IL-6 SNPs were analyzed by PCR
amplification. US was performed to assess the bone surfaces of metacarpophalengeal (MCP), proximal
interphalangeal (PIP) and metatarsophalangeal (MTP) joints by obtaining multiplanar scans. According to the
number of erosions per joint, a semiquantitative score ranging from 0 to 3 was calculated in each anatomical site
to obtain a MCP total erosion score (TES), a PIP TES and a MTP TES, all ranging from 0 to 30, and a global patient
TES calculated as the sum of these scores (range, 0 to 90).
Results: Patients carrying the TGF-b 869TT genotype showed a statistically significant lower MTP TES than those
with the CC or CT genotype (mean MTP TES ± standard deviation for 869TT 6.3 ± 5.7 vs. 869CC/CT 11.7 ± 7.8; P =
0.011). Interestingly, patients with the TT genotype showed dichotomous behavior that was dependent on
autoantibody status. In the presence of ACPAs and/or RF, the TT genotype was associated with lower erosion
scores at all anatomical sites compared with the CC and CT genotypes. Conversely, the same 869TT patients
showed higher erosion scores in the absence of ACPAs or RF.
Conclusions: In RA patients, TGF-b 869C/T SNPs could influence the bone-erosive damage as evaluated by US. The
serological autoantibody status (ACPAs and RF) can modulate this interaction.
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Introduction
Rheumatoid arthritis (RA) is a chronic, systemic inflam-
matory disease affecting primarily the joints. Its preva-
lence is approximately 0.5% to 1% in the industrialized
countries [1]. The genetic background of patients with
RA is responsible for at least part of the disease suscept-
ibility and phenotype as demonstrated by twin and family
studies. The human leukocyte antigen (HLA)-DRB1
shared epitope (SE) locus is strongly associated with the
disease, accounting for approximately one-third of the
genetic component of RA susceptibility [2]. Thus, other
non-HLA genes may play a role in RA disease develop-
ment, and previous research has focused on genes encod-
ing for cytokines in key pathogenetic pathways.
Transforming growth factor b (TGF-b) is a modulator of
the immune response in RA. The effects exerted by this
cytokine are midway between pro- and anti-inflamma-
tory, depending on several, mostly unveiled, factors.
TGF-b promotes the differentiation of leukocytes while
inhibiting the proliferation of T lymphocytes and the
activation of monocytes and/or macrophages [3].
Recently, three independent study groups simultaneously
discovered that if TGF-b is displaced in an inflammatory
milieu, it might act synergistically with IL-6 to induce the
differentiation of naive T cells into Th17 cells [4-6]. This
cell lineage is characterized by the production of IL-17, a
proinflammatory cytokine associated with joint inflam-
mation, osteoclastogenesis and the development of bone-
erosive damage [7]. IL-6 is one of the main determinants
of inflammation in RA. Indeed, it promotes the synthesis
of acute phase reactants by the liver, can regulate inflam-
matory and/or immune pathways and modulate bone
metabolism and endocrine function [8].
Single nucleotide polymorphisms (SNPs) of the TGF-b
and IL-6 genes (869C/T and -174G/C, respectively) have
been associated with RA susceptibility and radiographic
severity of bone-erosive damage [9-13]. Nowadays, con-
ventional radiography is considered a well-established
imaging technique for identifying progressive joint
damage. However, musculoskeletal ultrasound (US) is
more sensitive in the detection of soft-tissue lesions and
bone erosion [14].
The first aim of our study was to analyze whether
TGF-b 869C/T and IL-6 -174G/C are associated with
bone-erosive damage on the basis of US evaluation in a
cohort of RA patients starting anti-TNF treatment. A
secondary aim was to assess whether these SNPs could
influence US bone erosion progression after six months
of anti-TNF therapy.
Materials and methods
Seventy-seven patients with established RA diagnosed
according to the 1987 revised American College of
Rheumatology (ACR) criteria [15], were enrolled at the
Rheumatology Unit of Sapienza University of Rome.
Patients’ diagnoses were confirmed according to the
recently published European League Against Rheuma-
tism (EULAR)/ACR 2010 criteria [16]. The patients
started anti-TNF therapy with either subcutaneous ada-
limumab 40 mg every other week (n = 12) (Humira;
Abbott Laboratories Ltd, Vanwall Business Park, Van-
wall Road, Maidenhead, Berkshire, UK) or subcutaneous
etanercept 50 mg once per week (n = 65) (Enbrel;
Wyeth Europa Ltd., Huntercombe Lane South, Taplow,
Maidenhead, Berkshire, UK) for severely active disease
refractory to conventional therapy with disease-modify-
ing antirheumatic drugs (DMARDs). The patients were
studied before anti-TNF treatment was started (baseline
= T0) and at three and six months after initiation of
anti-TNF therapy (T3 and T6, respectively). DMARD
and glucocorticoid doses were maintained at a stable
level during follow-up. The local ethical committee
approved the study, which was performed according to
the Declaration of Helsinki criteria, and all patients pro-
vided their written informed consent for participation in
the study.
Clinical evaluation
All patients were evaluated by the same rheumatologist
(FC). Data were collected and entered into a standar-
dized, computerized, electronically filled-in form as pre-
viously described [17]. Data included patient
demographics, date of diagnosis, comorbidities and pre-
vious and concomitant medications. The clinical evalua-
tion included a count of swollen and tender joints and
the patient’s and physician’s global disease assessment
based on a visual analogue scale (VAS; range, 0 to 100
mm). Disease activity was measured according to the
disease activity score in 28 joints (DAS28), and the clini-
cal response was evaluated according to the EULAR
response criteria [18]. The patients were asked to fill in
the Health Assessment Questionnaire (HAQ) [19].
Laboratory analysis
Blood samples were obtained from all subjects, and
genomic DNA and sera were collected using standard
protocols and stored at -70°C until use. Rheumatoid fac-
tor (RF) (normal value < 17 IU/mL) (Behring, Marburg,
Germany) and anticitrullinated protein/peptide antibo-
dies (ACPAs) (normal value < 5 IU/mL) (Axis-Shield
plc, Dundee, UK) were detected by ELISA according to
the manufacturers’ instructions. For each patient, we
also measured the erythrocyte sedimentation rate (nor-
mal value < 20 mm/hour) by using the Westergen
method, as well as the C-reactive protein level (normal
value < 5 mg/dL).
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Genotyping
DNA was extracted from ethylenediaminetetraacetic
acid-treated peripheral blood using an automated metho-
dology (Maxwell 16; Promega, Madison, WI, USA) and
dedicated kits (Maxwell 16 Blood DNA Purification Kit;
Promega). The 869C/T SNP was analyzed by PCR ampli-
fication and digestion with a site-specific restriction
enzyme in accordance with previously reported methods
[13]. The forward and reverse primers were 5’-
TTCCCTCGAGGCCCTCCTA-3’ and 5’-GCCGCAG
CTTGGACAGGATC-3’, and the PCR amplification pro-
tocol was composed of 35 cycles comprising three steps
each: 75 seconds at 96°C, 75 seconds at 62°C and 75 sec-
onds at 73°C. PCR products were digested with MspA1I
(New England BioLabs, Ipswich, MA, US) and run on a
3% ethidium bromide-stained agarose gel.
The -174G/C IL-6 promoter SNP was analyzed by
PCR amplification and digestion with a site-specific
restriction enzyme using previously reported methods
[20]. The forward and reverse primers were 5’-
TGACTTCAGCTTTACTCTTGT-3’ and 5’-CTGATTG-
GAAACCTTATTAAG-3’, and the PCR amplification
protocol was composed of 39 cycles comprising three
steps each: one minute at 95°C, one minute at 55°C and
one minute at 72°C. PCR products were digested with
NlaIII (New England BioLabs, Ipswich, MA, US) and
run on a 3.5% ethidium bromide-stained agarose gel.
Musculoskeletal ultrasound assessment
US imaging was performed by using a MyLab70 XVG
machine (Esaote S.p.A., Florence, Italy) equipped with a
6- to 18-MHz linear probe. By using a fixed 18-MHz fre-
quency, bone surfaces of metacarpophalangeal (MCP),
proximal interphalangeal (PIP) and metatarsophalangeal
(MTP) joints were studied on multiplanar scans in accor-
dance with the EULAR US guidelines [21]. We chose
these joints because previous reports have shown that
bone erosion in RA may preferentially develop in the
small joints of the feet and hands at early stages of the
disease [22]. Gel was applied to the skin to provide an
acoustic interface. The first through the fifth MCP joints
of both hands, the first interphalangeal and the second
through fifth PIP joints of both hands, and the first
through fifth MTP joints of both feet were scanned. Each
joint was scanned in both the longitudinal and transverse
planes from the medial to lateral sides on both volar and
dorsal aspects to enable maximum coverage of the joint
surface area. To increase the acoustic window or access
of the transducer between the joints of specific fingers,
the fingers were splayed and then made into a fist. The
scans were obtained independently on the same day by
two rheumatologists (FC and CP) trained and experi-
enced in sonography. Each sonographer was blinded to
the sonographic findings of the other observer, but not to
the diagnosis. Bone erosion was assessed according to the
Outcome Measures in Rheumatoid Arthritis Clinical
Trials (OMERACT) definitions [23]. Based on the num-
ber of erosions per joint, a semiquantitative score ranging
from 0 to 3 was applied (grade 0 = no erosion, grade 1 =
one erosion, grade 2 = two erosions and grade 3 = at
least three erosions). The sum of the scores per joint in
articulations from the same anatomical site gave the
MCP, PIP and MTP total erosion score (TES) (MCP
TES, PIP TES and MTP TES, respectively; range, 0 to
30). A global patient TES was obtained by calculating the
sum of these scores (range, 0 to 90). All scores were the
means ± standard deviations (SDs) of the scores obtained
by the independent evaluation of the two sonographers.
Statistical analysis
The statistical analyses were performed using the Statis-
tical Package for Social Sciences version 13.0 software
(SPSS, Inc., Chicago, IL, USA). Comparisons of gene
and genotype frequencies between the groups were per-
formed by using contingency tables and Pearson’s c2
test. Corrections were made where necessary for the
sample size (Fisher’s exact test). Normally distributed
variables were summarized using the means (± SD), and
non-normally distributed variables were expressed as
medians and interquartile ranges. The comparisons
between nonparametric variables were performed using
the Mann-Whitney U test. Kruskal-Wallis one-way ana-
lysis of variance was applied to evaluate the comparisons
between multiple groups. The Bonferroni correction was
adopted (Pc). Pearson’s and Spearman’s tests were used
to perform the correlation analysis. Interobserver repro-
ducibility was determined using  statistics, and  values
were evaluated according to the method of Landis and
Koch [24]. All the P values were two-tailed, and P <
0.05 was considered significant.
Results
Demographics, clinical and laboratory features
The demographics and the clinical and laboratory fea-
tures of the 77 RA patients are given in Table 1. At the
time of study entry, our patients showed moderately to
severely active disease (mean DAS28 (± SD) 5.2 ± 1.2)
and moderate functional disability (mean HAQ (± SD)
1.26 ± 0.8). Fifty-eight patients (75.3%) were ACPA-
positive, while 61 (79.2%) were RF-positive. Concerning
concomitant treatment for RA, 48 patients (62.3%) were
taking corticosteroids and 53 (68.8%) were being treated
with at least one DMARD.
Ultrasonographic evaluation
All the evaluated patients showed the presence of ero-
sions (patient TES range, 2 to 90). The mean US erosion
scores at baseline (T0) are given in Table 1. MCP joints
Ceccarelli et al. Arthritis Research & Therapy 2011, 13:R111
http://arthritis-research.com/content/13/4/R111
Page 3 of 10
showed a significantly higher number of erosions com-
pared with the PIP and the MTP joints (P = 0.005 and
P = 0.03, respectively). Considering the erosive damage
according to ACPA status, autoantibody-positive
patients showed higher patient TES, although these
scores were not statistically significant, compared with
the ACPA-negative patients (mean ± SD 36.7 ± 23.4 vs.
24.4 ± 17.7; P = NS). Analogously, RF-positive patients
showed higher patient TES compared with RF-negative
patients (mean ± SD 35.6 ± 23.2 vs. 28.1 ± 16.4; P =
NS). Mean patient TES increased at T3 (mean ± SD
40.3 ± 22.8) and at T6 (mean ± SD 40.5 ± 22.4) (P =
NS for both comparisons) (see Table 2).
Patients showed a significant DAS28 reduction at T3
(P < 0.0001) and remained substantially stable at T6.
According to the EULAR criteria, a good or moderate
clinical response was achieved in 63.5% of patients at T3
and in 56.8% of patients at T6 (Table 2). At baseline,
patient DAS28 and TES showed a positive correlation (P
= 0.01). Changes in DAS28 did not correlate with
changes in TES at T3 or T6.
Association of bone-erosive damage with TGF-b 869C/T
SNP
Twenty-three patients (29.8%) had the TGF-b 869CC
genotype, 34 (44.2%) had the TGF-b 869CT genotype
and the remaining 20 (26%) had the TGF-b 869TT gen-
otype. After subgrouping the patients according to geno-
type, no significant differences were observed among the
three groups of patients at baseline with regard to mean
age, disease duration, ACPA or RF status, disease activ-
ity or disability (Table 3).
Interestingly, MTP TES was statistically significantly
different between TT genotype patients and those with
the CC or CT genotype (mean ± SD MTP TES 869TT:
6.3 ± 5.7 vs. 869CC/CT: 11.7 ± 7.8; P = 0.011) (Table
3). The same results were observed when correction for
disease duration was performed.
To determine whether the effect of TGF-b SNP on
bone-erosive damage could have been influenced by
ACPA and RF status, a comparison between autoanti-
body-positive and autoantibody-negative patients was
performed (Table 4). Patients with the 869TT genotype
(T allele) showed dichotomous behavior depending on
autoantibody status. In the presence of ACPA, these
patients showed a trend toward lower erosion scores at
all anatomical sites studied compared with ACPA-posi-
tive patients with the CC or CT genotype (C allele).
MTP TES was statistically significantly different between
ACPA-positive patients with the T allele and those with
the C allele (CC vs. TT Pc < 0.01 and CT vs. TT Pc <
0.05) (Table 4). Similarly, MTP TES was statistically sig-
nificantly lower in RF-positive patients with the T allele
compared with those with the C allele (CC vs. CT Pc <
0.05 and CT vs. TT Pc < 0.05, respectively). Conversely,
in seronegative patients, a trend toward higher erosion
scores was observed for patients with the T allele com-
pared with those with the C allele. RF-negative patients
with the TT genotype showed significantly higher PIP
TES compared with those with the CC genotype (Pc <
0.05).
We also assessed whether the TGF-b 869C/T SNP
could have influenced US bone erosion progression dur-
ing six months of anti-TNF therapy. As shown in Figure
1, after stratifying for TGF-b genotypes, there were no
statistically significant differences in US-identified pro-
gression of patient TES at T3 or T6.
Association of bone-erosive damage with IL-6 -174G/C
Forty-eight patients (62.3%) had the IL-6 -174GG geno-
type, 24 patients (31.2%) had the IL-6 -174GC genotype
and the remaining 5 patients (6.5%) had the IL-6
Table 1 Clinical, laboratory and ultrasonographic
characteristics of the 77 enrolled RA patients at study
entrya
Characteristics Data
Demographics
Males/females, n (%) 10 (13)/67 (87)
Mean age, years (± SD) 55.9 ± 14.3
Mean disease duration, months (± SD) 119.2 ± 93.6
Caucasian, n (%) 67 (87)
Hispanic, n (%) 9 (11.7)
African, n (%) 1 (1.3)
Laboratory results
RF-positive, n (%) 61 (79.2)
ACPA-positive, n (%) 58 (75.3)
Mean ESR, mm/hour (± SD) 31.8 ± 24.7
Clinical status (± SD)
Mean DAS28 score 5.2 ± 1.2
Mean HAQ score 1.26 ± 0.8
Concomitant treatment
Corticosteroids, n (%) 48 (62.3)
DMARDs, n (%)
Methotrexate 37 (48.0)
Hydroxychloroquine 16 (20.8)
Salazopyrin 15 (19.5)
Leflunomide 9 (11.7)
Mean US results (± SD)
Overall patient TES 33.4 ± 21.9
MCP TES 13.2 ± 8.1
PIP TES 9.7 ± 8.1
MTP TES 10.4 ± 8
aACPA: anticitrullinated protein/peptide antibody; DAS28: disease activity
score in 28 joints; DMARD: disease-modifying antirheumatic drug; ESR:
erythrocyte sedimentation rate; HAQ: Health Assessment Questionnaire; MCP:
metacarpophalangeal; MTP: metatarsophalangeal; PIP: proximal
interphalangeal; RA: rheumatoid arthritis; RF: rheumatoid factor; SD: standard
deviation; TES: total erosion score; US: musculoskeletal ultrasound.
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-174CC genotype. After stratifying the patients accord-
ing to IL-6 -174 genotype (Table 5), no significant dif-
ferences were observed among the subgroups of patients
with regard to mean age, ACPA and RF status, disease
activity and disability. Patients with the -174CC geno-
type (C allele) had a significantly lower disease duration
compared with those with the GG genotype (P = 0.01).
A statistically significantly lower MTP TES was observed
in patients with the -174GC genotype compared with
those with the CC genotype (P = 0.007) (Table 5).
After subgrouping the patients according to their
autoantibody status, no differences were found with
respect to genotype. Furthermore, we assessed whether
the IL-6-174G/C SNP could have influenced US-identi-
fied bone erosion progression during six months of fol-
low-up. After stratifying for the IL-6 -174SNP
genotypes, we observed a trend toward a higher rate of
progression of bone-erosive damage at T3 and T6 for
patients with the -174G allele (GG/GC genotypes).
Association with response to anti-TNF treatment
After stratifying the patients according to the TGF-b or
IL-6 genotype, we observed no significant differences in
the proportion of EULAR responders (data not shown).
Interestingly, all patients carrying the IL-6 -174CC
genotype showed a moderate or good clinical response
according to the EULAR criteria after six months of fol-
low-up.
Interobserver reproducibility
Interobserver agreement was statistically significant with
regard to bone erosions (P < 0.0001). A comparison of
the results from the two sonographers showed that the
overall unweighted  value for the examined joints was
0.72 (agreement in 87.5% of examinations).
Discussion
In the present study, we have shown that the TGF-b
869C/T SNP could influence the bone-erosive damage
evaluated by US in RA patients. Genetic factors are
implicated in RA pathogenesis, as they can influence not
only RA susceptibility but also clinical and radiological
severity and progression [25]. Genetic variants of candi-
date genes encoding for several cytokines (for example,
IL-1, IL-6, IL-10 and TGF-b), proteases (for example,
protein tyrosine phosphatase nonreceptor type 22) and
other immune/inflammatory genes (for example, macro-
phage protein 1) have been investigated with contrasting
results. When the candidate gene approach was used
previously, the study limitations were a lack of statistical
Table 2 Modification of mean DAS28 and TES of the 77 RA patients and patient response percentages according to
EULAR criteria at baseline (T0) and after three months (T3) and six months (T6) of anti-TNF therapya
Outcome measure T0 T3 T6 P value
Mean DAS28 (± SD) 5.2 ± 1.2 3.9 ± 1.6 3.8 ± 1.4 T0 vs. T3 < 0.0001
EULAR response - -
Good (%) 25 31.8
Moderate (%) 38.5 25
None (%) 36.6 43.2
Mean overall patient TES (± SD) 33.4 ± 21.9 40.3 ± 22.8 40.5 ± 22.4 NS
aDAS28: disease activity score in 28 joints; EULAR: European League Against Rheumatism; NS: not significant; PIP: proximal interphalangeal; RA: rheumatoid
arthritis; TES: total erosion score; TNF, tumor necrosis factor.
Table 3 Characteristics of the 77 RA patients stratified by TGF-b 869C/T SNPs at baseline (T0) and after three months
(T3) and six months (T6) of anti-TNF therapya
Characteristics T0 T3 T6 P value
Mean age, years (± SD) 55.9 ± 14.3 57.1 ± 13.9 56.7 ± 14.1 NS
Mean disease duration, months (± SD) 118.8 ± 93.6 116.4 ± 94.8 118.8 ± 94.8 NS
RF-positive, n (%) 18 (78.2) 29 (85.2) 14 (70) NS
ACPA-positive, n (%) 16 (69.5) 28 (82.3) 14 (70) NS
Mean DAS28 (± SD) 5.3 ± 1.1 5.2 ± 1.1 4.8 ± 1.2 NS
Mean HAQ score (± SD) 1.2 ± 0.7 1.34 ± 0.8 1.28 ± 0.8 NS
Mean overall patient TES (± SD) 34.1 ± 22.1 34.7 ± 24.4 29.5 ± 16.8 NS
Mean MCP TES (± SD) 14.7 ± 8.8 12.6 ± 8.6 12.4 ± 6.2 NS
Mean PIP TES (± SD) 8 ± 7.1 10.3 ± 8.9 10.6 ± 7.8 NS
Mean MTP TES (± SD) 11.3 ± 9 11.7 ± 7.8 6.3 ± 5.7 *P
aACPA: anticitrullinated protein/peptide antibody; DAS28: disease activity score in 28 joints; HAQ: Health Assessment Questionnaire; MCP: metacarpophalangeal;
MTP: metatarsophalangeal; PIP: proximal interphalangeal; RA: rheumatoid arthritis; RF: rheumatoid factor; TES: total erosion score; TGF-b: transforming growth
factor b. *P < 0.05, CC vs. TT; P = 0.01, CT vs. TT.
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power, small cohort dimensions and lack of replication
studies [26].
To the best of our knowledge, published data on the
effects of polymorphisms on bone-erosive damage in RA
have been obtained exclusively on the basis of conven-
tional radiographic assessment [26]. This technique is
considered the current standard for the assessment of
joint damage in RA [16], but it lacks the capability to
detect early bone-erosive damage [27]. Musculoskeletal
US is an easily reproducible, time-sparing and relatively
low-cost technique that has gained an important role in
the evaluation of RA patients. US is increasingly being
used in clinical practice related to the standardization of
this technique on the basis of the EULAR guidelines
and OMERACT definitions [21,23]. US allows an accu-
rate depiction of soft tissues and bony changes at all
stages of the disease process. There is a significant cor-
relation between the degree of synovial inflammation as
documented by gray scale and power Doppler methods
and disease activity indices [28]. Overall, US is more
sensitive than radiography in detecting bone erosions in
MCP and MTP joints in patients with RA [29-31]. Most
of the erosions detected by US cannot be visualized by
conventional radiography unless they progress to radio-
graphically evident severe bone lesions, which occur
within a period of one to two years. Indeed, US can
detect up to seven times more erosions than plain radio-
graphy in early RA [32,33].
We evaluated the TGF-b 869C/T and IL-6 -174G/C
genetic variants in 77 RA patients with respect to the
bone-erosive damage evaluated by US. We chose these
SNPs for their potentially key interacting roles in
Table 4 Bone-erosive damage assessed on the basis of US scores across TGF-b 869C/T SNPs according to ACPA and RF
statusa
Patient status CC CT TT P value
ACPA-positive
Mean overall patient TES (± SD) 39.5 ± 21.4 39.4 ± 26.3 23.7 ± 13.7 NS
Mean MCP TES (± SD) 16.7 ± 8.7 14.2 ± 9.1 11.2 ± 5.1 NS
Mean PIP TES (± SD) 9.4 ± 11.9 11.9 ± 9.8 7.7 ± 6.7 NS
Mean MTP TES (± SD) 13.3 ± 8.8 13.1 ± 8.3 4.75 ± 4.2 P = 0.008, Pc < 0.01; CC vs. TT
P = 0.01, Pc < 0.05; CT vs. TT
ACPA-negative
Mean overall patient TES (± SD) 24 ± 21.9 22 ± 11.1 38 ± 17.1 NS
Mean MCP TES (± SD) 11.5 ± 8.4 7.1 ± 3.6 14 ± 4.7 P < 0.05, Pc = NS; CT vs. TT
Mean PIP TES (± SD) 5.6 ± 5.3 6.1 ± 5.2 14.2 ± 7.8 P < 0.05, Pc = NS; CC vs. TT
Mean MTP TES (± SD) 6.8 ± 9.4 8.6 ± 4.8 9.8 ± 8.3 NS
RF-positive
Mean overall patient TES (± SD) 38 ± 22.4 37.6 ± 25.7 23.7 ± 13.7 NS
Mean MCP TES (± SD) 16.4 ± 8.9 13.8 ± 8.9 11.2 ± 5 NS
Mean PIP TES (± SD) 8.6 ± 7.6 11 ± 9.6 7.7 ± 6.7 NS
Mean MTP TES (± SD) 13 ± 9.1 12.7 ± 8.1 4.7 ± 4.2 P = 0.01, Pc < 0.05; CC vs. CT
P = 0.01, Pc < 0.05; CT vs. TT
RF-negative
Mean overall patient TES (± SD) 16.5 ± 8.7 27.4 ± 16.5 38 ± 17.1 P = 0.03, Pc = NS; CC vs. TT
Mean MCP TES (± SD) 7.5 ± 3.3 8.8 ± 6 14 ± 4.7 P = 0.03, Pc = NS; CC vs. TT
Mean PIP TES (± SD) 5 ± 3.5 9 ± 6.8 14.2 ± 7.8 P = 0.03, Pc < 0.05; CC vs. TT
Mean MTP TES (± SD) 4 ± 3.5 9.6 ± 8.3 9.8 ± 8.3 NS
aACPA: anticitrullinated protein/peptide antibody; MCP: metacarpophalangeal; MTP: metatarsophalangeal; NS: not significant; PIP: proximal interphalangeal; RF:
rheumatoid factor; TES: total erosion score; TGF-b: transforming growth factor b; US: musculoskeletal ultrasound. The comparisons were performed between
genotypes (CC vs. CT vs. TT groups) in ACPA-positive and ACPA-negative patients and in RF-positive and RF-negative populations, respectively, using Kruskal-
Wallis one-way analysis of variance. Pc: P values with the Bonferroni correction.
Figure 1 Representation of changes in US score according to
TGF-b 869C/T genotype after three and six months of anti-TNF
therapy.
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patients with RA. TGF-b is considered a pivotal cytokine
in the modulation of the immune response in RA. It
shows pro- and anti-inflammatory effects with a broad
range of biological functions, including wound healing,
fibrosis, immune suppression and angiogenesis [34]. It
has chemotactic properties and can stimulate cells to
produce IL-1, IL-6, TNF and other proinflammatory
cytokines at sites of inflammation [35]. It can have
immunosuppressive features by inhibiting the prolifera-
tion of T and B cells and the generation of T-cell cyto-
toxicity [36,37]. The TGF-b 869C/T SNP has been
widely evaluated in patients with RA. Studies of Japa-
nese and Chinese patient populations found an associa-
tion with disease susceptibility not confirmed in
Caucasians [11]. A recent meta-analysis underlined that
this SNP may play different roles in different ethnicities,
as genetic heterogeneity exists in different RA popula-
tions [11]. Yamada et al. [38,39] found higher TGF-b
serum concentrations in patients with CC genotype > >
CT genotype and > TT genotype, suggesting that the
869C/T substitution may affect signaling functions of
the peptide or the intracellular trafficking or export effi-
ciency of the protein. In our patient population, inde-
pendently of disease duration, patients with the C allele
the number of erosions at the MTP level were almost
twice those in patients with the T allele. The C-allele
carriers (who are supposed to have higher serum levels
of TGF-b) may show increased osteoclast activation
mediated by IL-17, leading to erosive damage. Enhanced
expression of TGF-b has been detected in synovial effu-
sion and synovium of patients with RA [40]. However,
surprisingly, these results were confirmed in ACPA- or
RF-positive patients but not in ACPA- or RF-negative
patients, in whom opposite results were obtained.
It has been shown that “seropositive” patients display
peculiar features, including more severe disease with
greater radiographic progression [41]. Our data may
support the hypothesis that the autoantibody-positive
RA patient population may differ from the so-called
“seronegative,” not only in clinical outcomes but also
with regard to genetic background and mechanism of
disease development. The SE allele has been associated
with RA only in ACPA-positive patients [42,43]. Because
of these considerations, we hypothesize that the dichoto-
mous behavior of TGF-b might be dependent on the
presence of autoantibodies that may interact at some
level with the TGF-b biologic pathway. In seropositive
patients, the presence of a more proinflammatory milieu
might switch TGF-b to exert its proinflammatory effects
with osteoclastogenic stimulation, leading to bone-ero-
sive damage. In this case, the presence of the C allele
might be responsible for the observed higher US-
detected bone-erosive damage. On the contrary, in sero-
negative RA patients, TGF-b might “switch” to exert
anti-inflammatory effects, which would explain the les-
ser bone damage in patients with the C allele. It cannot
be excluded that other as yet undiscovered factors may
be involved in such a dichotomy. In our study, on the
one hand, the inclusion of seropositive and seronegative
RA patients led to small subgroup sizes, but on the
other hand, this protocol may have helped to clarify the
hypothesis that these populations represent different
entities, even on a molecular basis. Larger cohorts are
required to better address this issue.
Only one previous study investigated the association
between TGF-b 869C/T gene SNP and radiographic
progression in RA. In agreement with our results, the
authors of that study showed that the T allele was not
associated with the Larsen score after correction for dis-
ease duration. The authors of that publication concluded
that the TGF-b 869C/T SNP was not associated with
structural severity. According to our results as well, the
same SNP is not associated with the progression of
structural damage [13].
IL-6 is a proinflammatory cytokine characterized by a
range of pleiotropic activities capable of mediating
Table 5 Characteristics of the 77 RA patients stratified by IL-6 -174G/C SNPa
Characteristics GG GC CC P value
Mean age, years (± SD) 57.5 ± 13.5 51.1 ± 16.1 61.4 ± 11.9 NS
Mean disease duration, months (± SD) 117.6 ± 74.4 144 ± 129.6 45.6 ± 19.2 P = 0.01; GG vs. CC
RF-positive, n (%) 39 (81.2) 17 (70.8) 4 (80) NS
ACPA-positive, n (%) 40 (83.3) 16 (66.6) 3 (60) NS
Mean DAS28 (± SD) 5.3 ± 1.2 4.8 ± 1.3 4.7 ± 0.8 NS
Mean HAQ score (± SD) 1.3 ± 0.7 1.3 ± 0.9 1.3 ± 0.7 NS
Mean overall patient TES (± SD) 36.2 ± 20.4 27 ± 21.8 35.4 ± 28.4 NS
Mean MCP TES (± SD) 14 ± 8.0 12 ± 8.4 12.4 ± 9 NS
Mean PIP TES (± SD) 10.3 ± 7.9 7.5 ± 7.6 13 ± 11.2 NS
Mean MTP TES (± SD) 11.9 ± 7.7 7.4 ± 8.1 10 ± 8.8 P = 0.007; GC vs. CC
aACPA: anticitrullinated protein/peptide antibody; DAS28: disease activity score in 28 joints; ESR: erythrocyte sedimentation rate; HAQ: Health Assessment
Questionnaire; IL: interleukin; MCP: metacarpophalangeal; MTP: metatarsophalangeal; NS: not significant; PIP: proximal interphalangeal; RA: rheumatoid arthritis;
RF: rheumatoid factor; SD: standard deviation; TES: total erosion score.
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cartilage and bone damage, including induction of acute
phase proteins and stimulation of T and B cells, syno-
viocytes and osteoclasts [44]. The presence of the G var-
iant at position -174 of the promoter region of the IL-6
gene leads to increased transcriptional activity and thus
to higher levels of the cytokine in serum and synovial
tissue in patients with RA [20,45]. In our study, patients
with the -174G allele showed higher rates of progression
of erosive damage (although not statistically significant)
even in the presence of longer disease duration at base-
line. This result is in agreement with the findings of pre-
vious studies. Indeed, the same -174G allele was
associated with higher disease severity evaluated with
the DAS28, and an allele-dose association of the IL-6
-174G variant with increasing radiographic damage was
observed in both ACPA-positive and RF-positive RA
patients [46].
None of the SNPs in the two genes influence the
response to TNF antagonist therapy. This has never
been previously addressed for TGF-b 869C/T, while few
data showing contrasting results are available for IL-6
-174C/G [47]. As mentioned above, in our study, the
MTP joints showed the highest sensitivity of change. It
cannot be excluded that statistical significance could
have been reached even at the MCP and PIP levels with
a larger patient cohort. Nevertheless, forefoot disease
activity appears to be frequent in patients with RA.
DAS28 score, which excludes forefoot disease from the
joint count, may underestimate disease activity com-
pared with DAS44. In a recent study conducted by van
der Leeden and colleagues [48], about 40% of the
patients who had DAS28 remission had at least one
painful and/or swollen MTP joint during the first eight
years of RA. These authors suggested that the DAS28
remission criterion for RA neglects patients with active
forefoot involvement. In addition to this clinical discre-
pancy, researchers in several studies have found that the
erosive disease in RA often begins in the small joints of
the feet, while the hands are affected only at a later
stage in the disease course [22]. This evidence is sup-
ported by the better sensitivity and specificity in diag-
nosing RA provided by combining hand and foot
radiographs than hand radiographs alone (as per the
1987 ACR criteria) [22,49-51]. More recently, Sheane
and colleagues [52] suggested that ultrasonographic
assessment of the fifth MTP joints may be useful in the
diagnosis of RA by identifying erosions and synovitis at
a very early stage. In a previous report published by our
group [53], MTP evaluation allowed a distinction to be
made between RA and undifferentiated arthritis in
patients with early arthritis, suggesting that MTP invol-
vement may be more specific for RA. Thus, evaluation
of bone-erosive damage at MTP joints should be per-
formed at an early stage in RA patients.
US has several intrinsic limitations, such as the pre-
sence of artefacts produced at the bone cortex, abnor-
mal setting of the machine (that is, increased pulse
repetition frequency, reduced gain and altered persis-
tence) and the incapability of penetrating the cortex to
identify subchondral lesions, cysts or bone marrow
lesions. Nonetheless, the main limits remain spreading
and standardization. Despite the great effort being made
to expand the use of US, this technique is not yet avail-
able to all rheumatologists in the evaluation of RA
patients. Moreover, there is a certain level of inter- and
intraobserver variability between ultrasonographers.
However, in the evaluation of bone erosions, US has
demonstrated good interobserver agreement in studies
reported in the literature [54]. In our study, to reduce
operator dependence to a minimum, the patients were
studied independently on the same day by two experi-
enced ultrasonographers. The results of the erosion
scores were the means of the scores recorded by the
two operators, and the interobserver agreement was
high and comparable to that reported in previous
studies.
Conclusions
In conclusion, our study confirms that genetic factors
are involved in determining the severity of bone damage
in RA as well as in predicting disease progression. Of
note, the TGF-b 869C/T SNP seems to have dichoto-
mous roles according to the patient’s autoantibody
(ACPA and RF) status. To the best of our knowledge,
this study is the first in which the roles of TGF-b and
IL-6 gene variants in bone-erosive damage were evalu-
ated with US. Further studies with larger patient series
and longer follow-up are needed.
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